SAR study on inhibitors of GIIA secreted phospholipase A2 using machine learning methods

GIIA secreted phospholipase A2 (GIIA sPLA2) is a potent target for drug discovery. To distinguish the activity level of the inhibitors of GIIA sPLA2, we built 24 classification models by three machine learning algorithms including support vector machine (SVM), decision tree (DT), and random forest (RF) based on 452 compounds. The molecules were represented by CORINA descriptors, MACCS fingerprints, and ECFP4 fingerprints, respectively. The dataset was split into a training set containing 312 compounds and a test set containing 140 compounds by Kohonen's self‐organizing map (SOM) strategy and a random strategy. A recursive feature elimination (RFE) method and an information gain (IG) method were used in the selection of molecular descriptors. Three favorable performing models were obtained. They were built by SVM algorithm with CORINA descriptors (Models 1A and 2A) and ECFP4 fingerprints (Model 10A). In the prediction of test set of Model 10A, the accuracy reached 90.71%, and the Matthews correlation coefficient (MCC) values reached 0.82. In addition, the 452 inhibitors were clustered into eight subsets by K‐Means algorithm for analyzing their structural features. It was found that highly active inhibitors mainly contained indole scaffold or indolizine scaffold and four side chains.

[1]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. , 1996, Journal of medicinal chemistry.

[2]  J. Burke,et al.  Mechanism of Inhibition of Human Nonpancreatic Secreted Phospholipase A by the Anti-inflammatory Agent BMS-181162 (*) , 1995, The Journal of Biological Chemistry.

[3]  G. Lambeau,et al.  Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities. , 2007, Journal of medicinal chemistry.

[4]  A. Yan,et al.  Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors , 2017, Molecular Diversity.

[5]  M. Büchler,et al.  Improved Method for the Determination of Phospholipase A2 Catalytic Activity Concentration in Human Serum and Ascites , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[6]  Chih-Jen Lin,et al.  A Practical Guide to Support Vector Classication , 2008 .

[7]  K. Tanaka,et al.  A novel type of phospholipase A2 inhibitor, thielocin A1 beta, and mechanism of action. , 1992, The Journal of antibiotics.

[8]  Nathan Halko,et al.  Finding Structure with Randomness: Probabilistic Algorithms for Constructing Approximate Matrix Decompositions , 2009, SIAM Rev..

[9]  Isabelle Guyon,et al.  Automatic Capacity Tuning of Very Large VC-Dimension Classifiers , 1992, NIPS.

[10]  M. Weyant,et al.  Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. , 2012, The Journal of thoracic and cardiovascular surgery.

[11]  N. Gensmantel,et al.  Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2. , 1994, Journal of medicinal chemistry.

[12]  Johann Gasteiger,et al.  A new model for calculating atomic charges in molecules , 1978 .

[13]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[14]  Dan Li,et al.  ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches. , 2016, Molecular pharmaceutics.

[15]  Y. Miki,et al.  A new era of secreted phospholipase A2 , 2015, Journal of Lipid Research.

[16]  D. Velmurugan,et al.  Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A2 group IIA, 5-lipoxygenase and cyclooxygenase-2. , 2016, Pharmacological research.

[17]  W Pruzanski,et al.  Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. , 1989, The Journal of biological chemistry.

[18]  Tingjun Hou,et al.  Constructing and Validating High-Performance MIEC-SVM Models in Virtual Screening for Kinases: A Better Way for Actives Discovery , 2016, Scientific Reports.

[19]  Katsutoshi Yamada,et al.  Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives. , 1996, Journal of medicinal chemistry.

[20]  W. Cantor,et al.  The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial , 2010, Circulation.

[21]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[22]  Thomas M. Mavromoustakos,et al.  Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor , 2010, J. Comput. Aided Mol. Des..

[23]  Tingjun Hou,et al.  ADMET evaluation in drug discovery: 15. Accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling , 2016, Journal of Cheminformatics.

[24]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. , 1996, Journal of medicinal chemistry.

[25]  G. Dive,et al.  Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives. , 2010, Bioorganic & medicinal chemistry.

[26]  J. Gasteiger,et al.  Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks , 1995 .

[27]  L. Lai,et al.  Quinoline-4-methyl esters as human nonpancreatic secretory phospholipase A₂ inhibitors. , 2011, Bioorganic & medicinal chemistry.

[28]  Youyong Li,et al.  ADMET Evaluation in Drug Discovery. Part 17: Development of Quantitative and Qualitative Prediction Models for Chemical-Induced Respiratory Toxicity. , 2017, Molecular pharmaceutics.

[29]  Luhua Lai,et al.  Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. , 2013, European journal of medicinal chemistry.

[30]  N. S. Yarla,et al.  Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents. , 2016, European journal of medicinal chemistry.

[31]  Youyong Li,et al.  ADMET Evaluation in Drug Discovery. 18. Reliable Prediction of Chemical-Induced Urinary Tract Toxicity by Boosting Machine Learning Approaches. , 2017, Molecular pharmaceutics.

[32]  K. Tanaka,et al.  Cinatrins, a novel family of phospholipase A2 inhibitors. II. Biological activities. , 1992, The Journal of antibiotics.

[33]  L. Gomez‐Paloma,et al.  Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. , 2007, Journal of medicinal chemistry.

[34]  G. Kokotos,et al.  Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016) , 2017, Expert opinion on therapeutic patents.

[35]  M. Lehr,et al.  Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2). , 2001, Bioorganic & medicinal chemistry letters.

[36]  L. Lai,et al.  Discovery of Novel Secretory Phospholipase A2 Inhibitors Using Virtual Screen , 2014, Chemical biology & drug design.

[37]  D.M. Mount,et al.  An Efficient k-Means Clustering Algorithm: Analysis and Implementation , 2002, IEEE Trans. Pattern Anal. Mach. Intell..

[38]  V. Madison,et al.  N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity. , 1993, Journal of medicinal chemistry.

[39]  M. Alcaraz,et al.  Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues. , 1998, Journal of medicinal chemistry.

[40]  N. Yoshida,et al.  Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation. , 1991, Enzyme.

[41]  M. Gelb,et al.  Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations. , 2016, Bioorganic & medicinal chemistry.

[42]  J.-P. Wery,et al.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.

[43]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[44]  Gisbert Schneider,et al.  Impact of descriptor vector scaling on the classification of drugs and nondrugs with artificial neural networks , 2004, Journal of molecular modeling.

[45]  Daisuke Fujioka,et al.  A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis , 2010, EMBO molecular medicine.

[46]  Thomas M. Mavromoustakos,et al.  Molecular Docking and 3D-QSAR CoMFA Studies on Indole Inhibitors of GIIA Secreted Phospholipase A2 , 2010, J. Chem. Inf. Model..

[47]  M. Payá,et al.  Synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases A2. , 2000, Bioorganic & medicinal chemistry letters.

[48]  Liang Cheng,et al.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. , 2002, The American journal of pathology.

[49]  M. Gelb,et al.  Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. , 2008, Bioorganic & medicinal chemistry letters.

[50]  Johann Gasteiger,et al.  Overcoming the Limitations of a Connection Table Description: A Universal Representation of Chemical Species , 1997, J. Chem. Inf. Comput. Sci..

[51]  Aixia Guo,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2014 .

[52]  N. S. Yarla,et al.  Phospholipase A2: A Potential Therapeutic Target in Inflammation and Cancer (In silico, In vitro, In vivo and Clinical Approach) , 2015 .

[53]  K. Tanaka,et al.  Isolation and biological activity of thielocins: novel phospholipase A2 inhibitors produced by Thielavia terricola RF-143. , 1995, The Journal of antibiotics.

[54]  T. Caliński,et al.  A dendrite method for cluster analysis , 1974 .

[55]  G. Morris,et al.  Molecular docking. , 2008, Methods in molecular biology.

[56]  M. V. D’Auria,et al.  New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions. , 2001, Journal of natural products.

[57]  R. Reid,et al.  Inhibitors of secretory phospholipase A2 group IIA. , 2005, Current medicinal chemistry.

[58]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[59]  Marcin Kozak,et al.  “A Dendrite Method for Cluster Analysis” by Caliński and Harabasz: A Classical Work that is Far Too Often Incorrectly Cited , 2012 .

[60]  Varnavas D. Mouchlis,et al.  Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations. , 2011, Bioorganic & medicinal chemistry.

[61]  Stan Szpakowicz,et al.  Machine Learning Applications in Mega-Text Processing , 2010 .

[62]  C. Unger,et al.  Synthesis and PLA2-inhibitory properties of 2(R)-acetamido-alkylphosphomethanols with a variable aggregate anchor. , 1999, Bioorganic & medicinal chemistry letters.

[63]  E. Dennis,et al.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. , 2011, Chemical reviews.

[64]  R. Rosenson,et al.  Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. , 2011, European heart journal.

[65]  John M. Knapp,et al.  Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3. , 2013, Bioorganic & medicinal chemistry letters.

[66]  E. Dennis,et al.  Phospholipase A2 Biochemistry , 2009, Cardiovascular Drugs and Therapy.

[67]  M. Gelb,et al.  The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. , 2006, Journal of medicinal chemistry.

[68]  H. Tojo,et al.  Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. , 1994, Gut.

[69]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[70]  J. Bronson,et al.  A simple synthesis of biaryl phospholipase A2 inhibitors: Probing hydrophobic effects , 1996 .

[71]  Johann Gasteiger,et al.  New empirical models of substituent polarisability and their application to stabilisation effects in positively charged species , 1983 .

[72]  Luhua Lai,et al.  Chemically induced dimerization of human nonpancreatic secretory phospholipase A2 by bis-indole derivatives. , 2008, Journal of medicinal chemistry.

[73]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. , 1996, Journal of medicinal chemistry.

[74]  Chang H. Park,et al.  Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines. , 2008, Bioorganic & medicinal chemistry.

[75]  L. Lai,et al.  Calculating partition coefficient by atom-additive method , 2000 .

[76]  M. Ogawa,et al.  Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. , 1994, British Journal of Cancer.

[77]  S. Wright,et al.  Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors , 1992 .

[78]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[79]  S. Katsumura,et al.  Design and synthesis of new secretory phospholipase A2 inhibitor of a phospholipid analog. , 1998, Bioorganic & medicinal chemistry letters.

[80]  M. Gelb,et al.  Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. , 2008, Journal of medicinal chemistry.

[81]  M. Alcaraz,et al.  A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration of cacospongionolides. , 1998, Journal of natural products.

[82]  Y. Miki,et al.  The Roles of the Secreted Phospholipase A2 Gene Family in Immunology , 2016, Advances in Immunology.

[83]  J. Kastelein,et al.  Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. , 2014, JAMA.